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Abstract
Objective
Individuals with attention-deﬁcit/hyperactivity disorder (ADHD) are at increased risk of
seizures, but there is uncertainty about whether ADHD medication treatment increases risk
among patients with and without preexisting seizures.
Methods
We followed a sample of 801,838 patients with ADHD who had prescribed drug claims from
the Truven Health MarketScan Commercial Claims and Encounters databases to examine
whether ADHD medication increases the likelihood of seizures among ADHD patients with
and without a history of seizures. First, we assessed overall risk of seizures among patients with
ADHD. Second, within-individual concurrent analyses assessed odds of seizure events during
months when a patient with ADHD received ADHDmedication compared with when the same
individual did not, while adjusting for antiepileptic medications. Third, within-individual long-
term analyses examined odds of seizure events in relation to the duration of months over the
previous 2 years patients received medication.
Results
Patients with ADHD were at higher odds for any seizure compared with non-ADHD controls
(odds ratio [OR] = 2.33, 95% conﬁdence interval [CI] = 2.24–2.42 males; OR = 2.31, 95%CI =
2.22–2.42 females). In adjusted within-individual comparisons, ADHD medication was asso-
ciated with lower odds of seizures among patients with (OR = 0.71, 95% CI = 0.60–0.85) and
without (OR = 0.71, 95% CI = 0.62–0.82) prior seizures. Long-term within-individual com-
parisons suggested no evidence of an association between medication use and seizures among
individuals with (OR = 0.87, 95% CI = 0.59–1.30) and without (OR = 1.01, 95% CI =
0.80–1.28) a seizure history.
Conclusions
Results reaﬃrm that patients with ADHD are at higher risk of seizures. However, ADHD
medication was associated with lower risk of seizures within individuals while they were
dispensed medication, which is not consistent with the hypothesis that ADHD medication
increases risk of seizures.
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Comorbidity between attention-deﬁcit/hyperactivity disor-
der (ADHD) and seizures is more common than expected.1
One explanation for the co-occurrence is that ADHD medi-
cation may induce seizures.2–13 In fact, the Physicians’ Desk
Reference warns that methylphenidate may lower seizure
threshold, resulting in (1) increased seizure frequency among
patients with ADHD and seizures, and (2) the occurrence of
new-onset seizures among patients with ADHD without
a history of seizures.13
Studies examiningwhether exposure tomethylphenidate,2–5,8,11,12
stimulants more broadly,6 and atomoxetine7,9 induce seizures
are limited by small samples2–5,7,8,10–12 and an inability to rule
out important confounding factors. Past research has also
often excluded patients with a seizure history12 or included
patients with an extended seizure-free period,2,3,12 raising
questions about clinical applicability of the ﬁndings for
patients with seizures. Thus, reviews have concluded that
there is not suﬃcient evidence to judge whether there is short-
and long-term harm of ADHD medication for seizures and
other rare events.14–19
The aim of the current study was to examine concurrent and
long-term associations between ADHD medication use and
seizures using a large national database of commercial health
insurance claims. The sample enabled us to estimate the
magnitude of the association among patients with and without
a seizure history with precision.13 Further, we assessed asso-
ciations within individuals, which eliminates confounding via
stable unmeasured factors, and accounted for time-varying
covariates, including use of antiepileptic medications.20–22
Methods
Sample
We used deidentiﬁed inpatient, outpatient, and prescribed
drug claims from the Truven Health MarketScan Commercial
Claims and Encounters databases. From 2005 to 2014, there
were approximately 146 million unique enrollee observations
in MarketScan, consisting of employees, COBRA (Consoli-
dated Omnibus Budget Reconciliation Act) continuees, non-
Medicare retirees, spouses, and dependents. Analysis of
MarketScan is considered exempt human participants’ re-
search by the University of Chicago institutional review board.
We included a sample of 801,838 (40.79% female) newly
treated patients with ADHD, deﬁned by a diagnosis of ADHD
(i.e., ICD-9 code 314.xx) or prescription of ADHD medica-
tion following at least 1 year in MarketScan without a di-
agnosis or prescription. We also selected this incident
diagnosis deﬁnition to identify those individuals who had no
claims for seizures for a least 1 year before the index date. We
included ADHD patients aged 5 to 64 years at the initial
diagnosis or initiation of medication during 2005–2014; un-
reliable diagnoses are more likely in younger children.23 We
followed patients with ADHD from their index date (i.e., ﬁrst
diagnosis or prescription ﬁll) until their last month of en-
rollment or to December 2014. We excluded years in which
patients did not have prescription coverage. If patients dis-
enrolled and then reenrolled, we followed them through their
ﬁrst disenrollment. Our sample selection procedure was
consistent with prior research using MarketScan data.24,25
ADHD medication
We identiﬁed ADHD medication using national drug codes
from ﬁlled prescription claims. Stimulant medications in-
cluded amphetamine salt combination, dexmethylphenidate
hydrochloride, dextroamphetamine sulfate, lisdexamfetamine
dimesylate, methamphetamine hydrochloride, methylpheni-
date, and methylphenidate hydrochloride. We also included
atomoxetine hydrochloride, a nonstimulant medication ap-
proved to treat ADHD. We deﬁned medication status
monthly and medicated months by a prescription receipt that
covered at least 1 day during a given month. Of the included
patients with ADHD, 526,495 (65.66%) had received at least
one prescription (table 1). Most patients received stimulant
medication only (88.61%), while a smaller number of patients
received atomoxetine only (4.80%) or both types of medi-
cations (6.59%).
Seizure events
We deﬁned seizure events as monthly claims for emergency
room visits, ambulance rides, or inpatient hospitalizations
Table 1 Summary statistics for included patients with
attention-deficit/hyperactivity disorder
Variable
Overall
No. %
Included patients 801,831 —
Medicated at least once 526,495 65.66
At least one medication switch 413,192 57.52
At least one seizure event 3,163 0.41
Median follow-up, mo (IQR) 16 (9–28)
Abbreviation: IQR = interquartile range.
Patients with at least onemedication status switch had at least 1monthwith
filled prescription coverage as well as at least 1 month with no prescription
coverage.
Glossary
ADHD = attention-deﬁcit/hyperactivity disorder; AED = antiepileptic drug; CI = conﬁdence interval; ICD-9 = International
Classiﬁcation of Diseases, Ninth Revision; OR = odds ratio.
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with ICD-9 codes (345.xx), excluding infantile spasms
(345.6x). This operationalization was consistent with that
used in prior analyses of MarketScan data,26–28 and was se-
lected in order to capture time-speciﬁc claims rather than
ongoing management of seizures. We determined seizure
history by any inpatient or outpatient claim with a seizure in
the database during the 1 year before the index date to in-
crease the likelihood of capturing seizure history.
Data analytic strategy
We made 3 sets of comparisons to assess the association
between ADHDmedication and seizures among patients with
and without a seizure history. We conducted all analyses in
SAS 9.4 (SAS Institute Inc., Cary, NC).
Overall risk of seizures among individuals with ADHD
We ﬁrst examined between-group diﬀerences. We used
logistic regression to assess the odds of (1) any seizure event
among patients with ADHD compared with matched non-
ADHD patient controls, (2) any seizure event among patients
with ADHD prescribed any medication compared with those
who were never prescribed ADHD medication, and (3) any
seizure event among patients with ADHD prescribed medi-
cation at least once compared with controls. We matched
patients with ADHD and controls 1:1 on sex, calendar year,
and age of ﬁrst enrollment in MarketScan, and length of en-
rollment in months. Our second analysis compared the risk,
within the ADHD patient group, of any seizure during
medicated months relative to unmedicated months, adjusted
for sex, calendar year, age of ﬁrst enrollment in MarketScan,
and length of enrollment in months.
Concurrent association of ADHD medication with
seizures
Second, we assessed concurrent associations between ADHD
medication and seizure events among patients with and
without a seizure history. We structured follow-up time by
months and used discrete-time logistic regression models.29
When new prescriptions for ADHD medication and seizures
occurred in the same month (n = 100), we coded months as
medicated if the seizure occurred after the date of the pre-
scription ﬁll (n = 51) and nonmedicated if the seizure oc-
curred before or on the date of the prescription ﬁll (n = 49).
For analyses including patients with a seizure history, we
permitted repeated events during follow-up. However, we
limited follow-up to ﬁrst events in the analyses including
patients with no seizure history, because once these patients
had a recorded seizure event, they should no longer be deﬁned
as such. This analysis also helps rule out reverse causation, as
having a seizure may decrease the subsequent likelihood of
being prescribed ADHD medication because of perceived
seizure risk.
We began with population-level models, which assessed the
odds of seizure events during medicated months compared
with unmedicated months while adjusting for sex and the
following measured time-varying covariates: age, calendar
year, and prescription of antiepileptic drugs (AEDs) (see
table e-1, links.lww.com/WNL/A291, for included AEDs).
Repeated-events, population-level models also adjusted for
time since last seizure event and the nonindependence of
observed months within individuals (PROC SURVEYLO-
GISTIC). The models, however, could not account for un-
measured factors that diﬀer between patients who did and did
not receive ADHD medication.
For our primary analyses, we used conditional logistic models
to compare medicated and nonmedicated months within
individuals to assess the association independent of stable
confounding factors while also adjusting for the time-varying
covariates (i.e., AEDmedication and time since last seizure for
repeated-events models). These models compared seizure
risk during periods when an individual received medication
relative to when the same individual did not receive medica-
tion. Because each individual serves as his/her own control,
this approach accounts for all unmeasured factors that are
stable within the individual (e.g., general severity of ADHD,
genetic predisposition for ADHD and/or seizures, general
seizure liability).
We conducted 6 sensitivity analyses to test the robustness of
our ﬁndings among all patients with ADHD, without strati-
ﬁcation for seizure history. First, we analyzed the association
with stimulant medication only because all stimulants have
similar mechanisms of action (i.e., increased available dopa-
mine),14 whereas atomoxetine is a norepinephrine reuptake
inhibitor.16 Second, we considered whether additional
psychotropic medications may be confounding the associa-
tion by examining the association by excluding persons with
psychotropic medication prescriptions, including an AED
prescription. Third, we conducted an analysis extending
ADHD medication exposure by 1 month to provide a more
conservative estimate of medication discontinuation. Fourth,
we considered the possibility that our outcome deﬁnition was
capturing the same event multiple times. To address this, we
restricted seizure events to emergency room visits only for
a more conservative index of seizure events. Fifth and sixth, we
conducted analyses separately by sex and among various age
groups to assess whether the associations diﬀer by sex or
among patients of diﬀerent ages.
Cumulative long-term association of ADHD
medications with seizures
Third, to examine whether long-term ADHD medication
receipt was associated with seizure risk, we examined the as-
sociation between the cumulative number of prescribed
months across 2 years and subsequent seizure events. Similar
to concurrent analyses, we began with population-level
models, but our primary analyses examined the association
within individuals. We included concurrent medication status
in all models to assess the cumulative association independent
of current medication eﬀects. Our population-level models
also adjusted for age, sex, calendar year, time since last seizure,
and AED prescription; within-individual models adjusted for
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time since last seizure event and AED prescription. Patients
included in analyses had 2 years of follow-up time. Months
prior to 2 years of follow-up were excluded. We conducted
similar sensitivity analyses as outlined above. We also exam-
ined a 3-year cumulative association, as well as the association
between ADHD medication and subsequent seizure events 2
and 3 years later.
Results
Overall risk of seizures among individuals
with ADHD
Demographic information is presented in table 1. We iden-
tiﬁed 474,742 (59.21%) male and 327,089 (40.79%) female
patients with ADHD. Median age at follow-up was 17 years
(interquartile range, 8–36). Of the 801,838 identiﬁed patients
with ADHD, we were able to match 801,831 with controls.
We present group comparisons in table e-2 (links.lww.com/
WNL/A291). Among patients with ADHD, 1.84% of male
and 2.06% of female patients had at least one seizure event,
compared with 0.80% of male and 0.90% of female controls
(odds ratio [OR] 2.33, 95% conﬁdence interval [CI]
2.24–2.42 males; OR 2.31, 95% CI 2.22–2.42 females). In
ever-medicated patients with ADHD, 1.44% of males and
1.63% of females had at least one seizure, compared with
2.14% of male and 2.58% of female never-medicated patients
with ADHD (OR 0.63, 95% CI 0.60–0.67 males; OR 0.61,
95% CI 0.57–0.64 females). Finally, male and female ever-
medicated patients with ADHD were at higher odds of any
seizure event compared with controls (OR 1.69, 95% CI
1.59–1.80 males; OR 1.61, 95% CI 1.52–1.71 females).
Concurrent association of ADHD medication
with seizures
Adjusted concurrent associations are presented in table 2. In
the adjusted population-level models, medicatedmonths were
associated with 43% lower odds of seizure events among
ADHD patients with a history of seizures. Among patients
without a seizure history followed up to ﬁrst events, medi-
cated periods were associated with 40% lower odds of seizure
events relative to unmedicated periods. More importantly, in
our within-individual comparisons, patients with a seizure
history were at 29% lower odds of seizure events during the
months in which they were medicated compared to non-
medication periods. Similarly, patients with no recorded prior
seizures were at 49% lower odds of a seizure event during
periods in which an individual was medicated compared to
when the same individual was not. Sensitivity analyses ex-
amining the association between ADHD medication and
seizures in various subcohorts and by varying the deﬁnition of
exposure and outcome provided commensurate results with
the main analyses (table 3).
We present point estimates for the inclusion of AEDs as
a time-varying covariate in our concurrent analyses in table e-3
(links.lww.com/WNL/A291). Overall, AED medication
prescription receipt was associated with increased risk of
seizure events. However, we do not take this to mean that
AED medication caused seizures. Rather, this association
likely reﬂects reverse causation, as individuals’ seizure status
and the ongoing management of seizures are likely re-
sponsible for the positive association.
Table 2 Adjusted concurrent associations between
attention-deficit/hyperactivity disorder
medication and seizures
Cohort
No. of
patients
No. of
seizures
Population-
level
Within-
individual
Repeated events
With any
prior seizure
9,739 2,890 0.57
(0.50–0.64)
0.71
(0.60–0.85)
First events
With no prior
seizure
792,099 1,675 0.60
(0.54–0.67)
0.51
(0.43–0.62)
Data represent count or odds ratio (95% confidence interval). The pop-
ulation models control for age, sex, calendar year, time since last seizure
event, and antiepileptic drug prescription. Within-individual models control
for time since last seizure event and antiepileptic drug prescription.
Table 3 Adjusted concurrent within-individual sensitivity
analyses
Sensitivity analyses
(within only)
No. of
patients
No. of
seizures OR (95% CI)
Repeated events
Stimulant only 801,838 5,427 0.74 (0.66–0.82)
No other psychotropic
medications
453,356 246 1.03 (0.57–1.86)
1-mo extended 801,838 5,427 0.72 (0.65–0.81)
ER only 801,838 3,539 0.81 (0.71–0.92)
Men only 474,744 3,105 0.68 (0.59–0.78)
Women only 327,094 2,322 0.74 (0.63–0.87)
Age group, y
5–6 81,089 873 0.95 (0.73–1.23)
7–12 223,045 1,345 0.68 (0.55–0.83)
13–17 130,535 1,156 0.57 (0.44–0.72)
18–25 144,115 910 0.88 (0.66–1.16)
26–35 78,188 396 0.53 (0.37–0.76)
36–45 73,491 374 0.58 (0.38–0.89)
46+ 71,375 373 0.79 (0.48–1.31)
Abbreviations: CI = confidence interval; ER = emergency room; OR = odds
ratio.
Within-individual models control for time since last seizure event and anti-
epileptic drug prescription (excluding the no other psychotropic medication
analysis).
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Cumulative long-term association of ADHD
medications with seizures
Next, we analyzed 2-year cumulative associations between
ADHD medication and seizure events (table 4). In the
population-level models, 2-year duration ofmedication was not
associated with seizure events among patients with and without
prior seizures. Our within-individual estimates produced simi-
lar results. In addition, varying our cohort, exposure, and out-
come deﬁnitions produced similar ﬁndings (table 5). We
present the point estimates for the inclusion of AEDs as a time-
varying covariate in our long-term analyses in table e-4 (links.
lww.com/WNL/A291). Again, point estimates likely reﬂect
ongoing management of seizures requiring AED medication.
Discussion
The results of this study are not consistent with the hypothesis
that ADHD medication increases seizure frequency and/or
induces new seizures in patients concurrently. Furthermore,
we found no evidence that long-term cumulative duration of
ADHD medication increases risk of seizures. Our ﬁndings
substantially expand on the current literature. Our use of large
insurance claims data allowed us to more precisely test the
association between ADHD medication and seizures while
using a design feature (i.e., within-individual comparisons) to
adjust for unmeasured confounding factors that are typically
unadjusted for by traditional between-individual compar-
isons. We provide converging evidence with the body of lit-
erature that has not found increased risk of seizures due to
ADHD medication,2–4,6–9,11,12 as well as one preliminary
study that has suggested that ADHD medication is associated
with decreased risk of seizures.30 Furthermore, we were able
to speciﬁcally examine whether the association between
ADHDmedication and risk of seizures diﬀers among patients
with and without a seizure history. Individuals with a history
are perceived to be most at risk of worsening of seizures as
a result of ADHD medication, and our outcome deﬁnition
Table 4 Adjusted long-term cumulative associations between ADHD medication and seizures
Cohort No. of patients No. of seizures
Population-level Within-individual
Long-term Concurrent Long-term Concurrent
Cumulative duration
Any prior seizure 3,480 805 0.88 (0.74–1.03) 0.79 (0.62–1.01) 0.87 (0.59–1.30) 0.79 (0.55–1.15)
No prior seizure 301,847 1,176 0.94 (0.82–1.08) 0.69 (0.55–0.87) 1.01 (0.80–1.28) 0.67 (0.53–0.85)
Abbreviation: ADHD = attention-deficit/hyperactivity disorder.
Data represent count or odds ratio (95% confidence interval). Cumulative associations are the odds of events predicted by the cumulative number ofmonths
medicated during the 2 years prior. Adjusted population models adjust for current ADHD medication status, age, sex, calendar year, time since last seizure
event, and antiepileptic drug prescription.Within-individualmodels adjust for current ADHDmedication status, time since last seizure event, and antiepileptic
drug prescription.
Table 5 Adjusted long-term cumulative and interval within-individual sensitivity analyses
Sensitivity analyses (within only) No. of patients No. of seizures Long-term Concurrent
Cumulative duration
3 y 193,612 1,246 1.06 (0.86–1.31) 0.68 (0.52–0.88)
Stimulant medication only 305,327 1,981 0.96 (0.78–1.17) 0.77 (0.63–0.95)
No other psychotropic medications 155,386 49 1.60 (0.41–6.30) 2.79 (0.60–12.97)
ER only 305,327 1,403 0.88 (0.69–1.11) 0.77 (0.61–0.98)
Men only 184,172 1,154 0.97 (0.74–1.27) 0.66 (0.50–0.86)
Women only 121,155 827 0.98 (0.73–1.32) 0.76 (0.56–1.02)
Time interval, y
3 193,612 1,246 1.07 (0.88–1.31) 0.69 (0.53–0.89)
2 305,327 1,981 0.95 (0.80–1.11) 0.69 (0.57–0.84)
Abbreviation: ER = emergency room.
Data represent count or odds ratio (95% confidence interval). Adjusted models adjust for current attention-deficit/hyperactivity disorder medication status,
time since last seizure event prescription of antiepileptic drugs. Cumulative associations are the odds of events predicted by the cumulative number of
months medicated during the 2 or 3 years prior. Interval associations are the odds of events predicted by medication status 2 or 3 years prior.
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likely captures particularly severe events (as they warranted
emergency or inpatient treatment). As such, the results do not
support the hypothesis that ADHD medication is responsible
for the comorbidity between ADHD and seizures. That is, we
found no evidence of increased risk of seizures as a result of
ADHD medication, regardless of seizure history.
There are several possible explanations for the ﬁnding that
ADHD medication was associated with lower odds of seizure
occurrence. If our ﬁndings reﬂect real protective eﬀects of
ADHDmedication, one explanation for lower risk may be that
ADHD medication treats symptoms of a shared mechanism
putting individuals at risk of both ADHD and
seizures.9,10,31–33 ADHD medication may also inﬂuence
seizures via increased AED compliance or reduction of pre-
cipitating factors, such as stress.34 An alternative explanation
for our ﬁndings is that individuals with seizures are not given
ADHDmedication because of the concern that it may worsen
their condition. ADHDmedication was associated with lower
odds of the occurrence of the ﬁrst seizure event among
patients without previous seizures, which may help rule out
this possibility. However, it is possible that individuals may
have had seizure events not recorded in our data, and we were
not able to examine whether physicians refrained from pre-
scribing ADHD medication to individuals with more severe
seizures. Future research will need to study these factors more
closely.
The comorbidity between ADHD and seizures may partially
explain concern surrounding ADHD medication, as physi-
cians are more likely to see seizure occurrence in individuals
with ADHD.2–9 This, taken together with our concurrent and
long-term ﬁndings, suggests that other factors may explain the
association between ADHD medication and seizures. These
ﬁndings are consistent with multiple hypotheses for why
ADHD co-occurs with seizures/epilepsies. First, the comor-
bidity may reﬂect a distinct or severe neurologic disorder18,31;
individuals with comorbid ADHD and seizures have more
severe symptoms compared with individuals with one di-
agnosis.29 Second, a shared underlying biological vulnerability
or cause may account for the comorbidity, including common
genetic32 or environmental factors (e.g., CNS injury)35 that
lead individuals to develop both ADHD and seizures. Third,
the comorbidity may be attributable to the inﬂuence of one
disorder on another.36 Speciﬁcally, ADHD symptoms may be
a consequence of seizures, either due to added brain insult via
seizures31 or due to AED-induced ADHD symptoms in
patients with seizures.37 Alternatively, ADHD may put an
individual at risk for CNS injury and, therefore, seizures.35
Our ﬁndings are subject to several limitations. First, because
we used an observational design, we cannot draw deﬁnitive
causal conclusions; time-varying factors that were not mea-
sured or measured imperfectly may still confound the asso-
ciation. For example, we cannot rule out the possibility that
the ﬁndings reﬂect an association with general treatment
engagement. In contrast to previous studies that used other
psychotropic medications as a negative control to address this
concern,20–22,25 we were unable to do so because such med-
ications are known to be associated with seizure activity.38–40
Second, atomoxetine was the only included nonstimulant
ADHD medication; we did not explore atomoxetine alone
because the majority of research has focused speciﬁcally on
stimulant medications. Third, we examined the association
among patients with commercial health insurance in the
United States. We do not know how well our ﬁndings will
generalize to other populations (i.e., lack of insurance, Med-
icaid, Medicare) and other countries. Fourth, measurement
error regarding our exposure and outcome may have biased
our ﬁndings. Given that our data come from health insurance
claims, we cannot ensure medication compliance (i.e., if and
how frequently individuals who picked up their prescription
actually took their medication), and we do not know whether
individuals received medication not covered by insurance.
Our measure of seizure events (i.e., emergency department,
ambulance rides, and inpatient hospitalizations) and history
of seizures (i.e., any inpatient or outpatient seizure claims)
may not have captured all seizures. As such, we cannot ensure
that individuals identiﬁed to have no prior seizures may have
actually had seizures that were not captured in our data, and
seizure events that are captured are likely representative of
more severe seizures and/or epilepsies. It is important to note,
however, that nondiﬀerential misclassiﬁcation would attenu-
ate the associations, making the results and our conclusions
more conservative. Fifth, we were not able to diﬀerentiate
between seizure-free patients with ADHD who do and do not
have epileptiform EEG patterns. Future research should ad-
dress this; however, previous data have suggested no diﬀer-
ence among these groups.6
In sum, using a large commercial health insurance claims
database to examine the association between ADHD medi-
cation and risk of seizures in a cohort of ADHD patients with
and without a history of seizures, we observed lower risk of
seizures within individuals during medication periods com-
pared to nonmedication periods. While we do not take this to
mean that ADHD medication should be used as a treatment
for seizures, our ﬁndings suggest that concerns about ADHD
medication causing seizures should be mitigated as physicians
and patients weigh risks and beneﬁts of these medications.
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Study question
Do medications for attention-deﬁcit/hyperactivity disorder
(ADHD) increase the risk of seizures?
Summary answer
ADHD medications do not increase the risk of seizures.
What is known and what this paper adds
The prevalence of seizures in people with ADHD is higher than
expected, and some researchers have therefore hypothesized that
ADHD medications increase the risk of seizures. However, this
study provides evidence against that hypothesis.
Participants and setting
This study examined data for 801,838 patients with newly
treated ADHD and 801,831 age-, sex-, and year-matched
healthy controls. These data came from the 2005–2014 pe-
riod of the Truven Health MarketScan Commercial Claims
and Encounters databases.
Design, size, and duration
The study analyzed the overall risk of seizures among ADHD
patients relative to matched controls, the risk of seizures while
ADHD patients were prescribed ADHDmedications, and the
long-term risk of seizures following treatment with ADHD
medications. Importantly, analyses examined risk of ADHD
medication between medicated months and un-medicated
months in the population, as well as when the same individual
was medicated and un-medicated.
Primary outcomes
The primary outcome was a seizure event, as reﬂected in
monthly claims for seizure-related emergency room visits,
ambulance rides, and hospitalizations.
Main results and the role of chance
Of the participants, 526,495 (65.66%) received at least one
prescription. Compared to sex-matched healthy controls,
the occurrence of at least one seizure event was more
common in both male (odds ratio [OR], 2.33; 95% CI,
2.24–2.42) and female patients (OR, 2.31; 95% CI,
2.22–2.42). Within-individual analyses showed that the risk
of seizures was lower in on-medication months than in oﬀ-
medication months both in patients with prior seizures (OR,
0.71; 95% CI, 0.60–0.85) and in patients without such his-
tories (OR, 0.51; 95% CI, 0.43–0.62). However, no long-
term associations between ADHD medication usage and
seizure events were found.
Bias, confounding, and other reasons
for caution
The study’s observational nature precluded detection of causal
relationships. Atomoxetine was the only nonstimulant ADHD
medication examined. The data might not have reﬂected all
seizure events.
Generalizability to other populations
The study only examined persons in the US with commercial
health insurance. This may limit generalizability to US per-
sons without commercial health insurance and to persons in
other countries.
Study funding/potential competing interests
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Dr. Larson has served as a speaker for Eli Lilly and Shire and
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Population-level long-
term OR (95% CI)
Within-individual long-
term OR (95% CI)
Patients with
prior seizures
0.88 (0.74–1.03) 0.87 (0.59–1.30)
Patients without
prior seizures
0.94 (0.82–1.08) 1.01 (0.80–1.28)
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